CEDAR KNOLLS, N.J.,
Jan. 3, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and the
owner of Fortetropin®, a proprietary bioactive
composition derived from fertilized egg yolk that helps build lean
muscle, announced today that it received the United States Patent # 10,165,785
titled, "Process for Producing Composition for Increasing
Muscle Mass" from the United States Patent and Trademark
Office (USPTO) on January 1,
2019. This new patent significantly enhances MYOS' existing
intellectual property portfolio, enabling MYOS to protect its
advanced technologies for the development of innovative nutrition
products to address musculoskeletal health.
Joseph Mannello, Chief Executive
Officer of MYOS, commented, "I am delighted that the USPTO has
issued MYOS its most recent patent. I am committed to building a
world class company that is focused on redefining muscle health. In
order to meet that goal, MYOS has invested extensively in research
and development over the last several years. Currently, we
have preclinical and clinical studies underway at Kansas State University, Weill Cornell Medical
College and University of California,
Berkeley. I believe this new patent will prove vital as we
capitalize on our investments in R&D, enabling us to deliver
the maximum value to our shareholders."
The new patent covers an advanced, state-of-the-art
manufacturing process for a fertilized, egg yolk-derived
composition that was developed by researchers at the German
Institute of Food Technologies/DIL ("DIL") that helps maintain the
natural bioactivity of egg yolk without compromising its safety.
DIL has assigned full rights of this patent to MYOS. The processes
covered by our patents are used to manufacture nutrition products
that we have evaluated in the past, and are evaluating in our
current clinical and preclinical studies related to muscle
conditions such as sarcopenia and muscle disuse atrophy in both
humans and domestic pets.
Dr. Volker Heinz, Director of DIL
and a co-inventor on the patent, commented, "We are extremely
pleased with the issuance of this most recent patent. Our
R&D collaboration with MYOS has been very exciting and
extremely fruitful. We look forward to continued collaboration with
MYOS to address muscle health through innovations in
nutrition."
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
About the German Institute of
Food Technologies/DIL (Deutsches Institut für
Lebensmitteltechnik e.V.)
The German Institute of Food
Technologies (DIL) is a world renowned advanced research
organization located at the heart of Germany's agriculture and food industry. A
very well-established team of around 200 scientists and engineers
collaborate to develop advanced and innovative technologies for
food production. With more than 170 member companies from the food
industry and related fields, DIL operates as a research institute
working in the areas of product development, process development
and analysis.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr®, Yolked®, MYOS
Enteral Nutrition Formula™ and MYOS Canine Muscle
Formula™ products, the success of our research and development,
the results of the clinical evaluation of
Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter
LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-receives-a-new-patent-from-the-united-states-patent-and-trademark-office-300772179.html
SOURCE MYOS RENS Technology